inclusion criteria: 1. subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. 2. male or female in aged 18 and older. 3. expected survival time, not taking into account sarscov2 infection, is at least 6 months. 4. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). 5. hospitalization due to covid 19 disease or disease with accompanied covid 19. 6. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). 7. initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": 1. plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l\>100) 2. saa \>100mg/l 3. leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul 4. crp \>100 mg/l and absolute lymphopenia 5. il-6 \>25 pg/ml 6. inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: 1. increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) 2. increase of saa concentration by at least 25% compared to initial result (at least a day before) 3. decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) 4. increase of crp by at least 50% compared to initial result (at least a day before) 5. increase of il-6 by at least 25% compared to initial result (at least a day before) 6. progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) 7. decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg

inclusion criteria: 1. subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. 2. male or female in aged 18 and older. 3. expected survival time, not taking into account sarscov2 infection, is at least 6 months. 4. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). 5. hospitalization due to covid 19 disease or disease with accompanied covid 19. 6. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). 7. initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": 1. plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l\>100) 2. saa \>100mg/l 3. leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul 4. crp \>100 mg/l and absolute lymphopenia 5. il-6 \>25 pg/ml 6. inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: 1. increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) 2. increase of saa concentration by at least 25% compared to initial result (at least a day before) 3. decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) 4. increase of crp by at least 50% compared to initial result (at least a day before) 5. increase of il-6 by at least 25% compared to initial result (at least a day before) 6. progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) 7. decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg

inclusion criteria: subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. male or female in aged 18 and older. expected survival time, not taking into account sarscov2 infection, is at least 6 months. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). hospitalization due to covid 19 disease or disease with accompanied covid 19. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l>100) saa >100mg/l leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul crp >100 mg/l and absolute lymphopenia il-6 >25 pg/ml inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) increase of saa concentration by at least 25% compared to initial result (at least a day before) decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) increase of crp by at least 50% compared to initial result (at least a day before) increase of il-6 by at least 25% compared to initial result (at least a day before) progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg

inclusion criteria: subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. male or female in aged 18 and older. expected survival time, not taking into account sarscov2 infection, is at least 6 months. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). hospitalization due to covid 19 disease or disease with accompanied covid 19. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l>100) saa >100mg/l leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul crp >100 mg/l and absolute lymphopenia il-6 >25 pg/ml inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) increase of saa concentration by at least 25% compared to initial result (at least a day before) decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) increase of crp by at least 50% compared to initial result (at least a day before) increase of il-6 by at least 25% compared to initial result (at least a day before) progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg

inclusion criteria: 1. subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. 2. male or female in aged 18 and older. 3. expected survival time, not taking into account sarscov2 infection, is at least 6 months. 4. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). 5. hospitalization due to covid 19 disease or disease with accompanied covid 19. 6. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). 7. initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": 1. plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l>100) 2. saa >100mg/l 3. leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul 4. crp >100 mg/l and absolute lymphopenia 5. il-6 >25 pg/ml 6. inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: 1. increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) 2. increase of saa concentration by at least 25% compared to initial result (at least a day before) 3. decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) 4. increase of crp by at least 50% compared to initial result (at least a day before) 5. increase of il-6 by at least 25% compared to initial result (at least a day before) 6. progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) 7. decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg

inclusion criteria: 1. subject has signed informed consent form and is able to understand the purpose and procedures required for the study and is willing to participate in the study. 2. male or female in aged 18 and older. 3. expected survival time, not taking into account sarscov2 infection, is at least 6 months. 4. diagnosis of covid 19 disease confirmed by sarscov2 pcr test (the validity of test 7 days before the start of screening). 5. hospitalization due to covid 19 disease or disease with accompanied covid 19. 6. any of the following: use of oxygen therapy or oxygen therapy and remdesivir or use of oxygen therapy and convalescent plasma or use of oxygen therapy and remdesivir and convalescents plasma or no necessity of using oxygen therapy but necessity of using remdesivir or convalescents plasma or remdesivir and convalescents plasma (which corresponds to the disease severity of 4-6 points in covid 19 performance status scale). 7. initially escalated inflammatory process, defined as compliance at least 2 parameters from group "a", during 24 hours before including patient to the study or at least one parameter from group "b". group "a": 1. plasma amyloid a to lymphocyte count ratio is greater than 100 (saa/l>100) 2. saa >100mg/l 3. leukocytosis (wbc) over 10 k/ul with absolute lymphopenia under 1,0 k/ul 4. crp >100 mg/l and absolute lymphopenia 5. il-6 >25 pg/ml 6. inflammatory changes in lung assessed based on high resolution computed tomography (hrct) at least 2 points in covid-ct scale. group "b": inflammatory process progression during the hospitalization (optimally during 2 days and maximum during 7 days) compared to starting tests: 1. increase of plasma amyloid a (saa) to lymphocyte count ratio (saa/l) by at least 25% compared to initial result (at least a day before) 2. increase of saa concentration by at least 25% compared to initial result (at least a day before) 3. decline of absolute lymphocyte count in peripheral blood by at least 25% compared to the initial result (from one day ago) 4. increase of crp by at least 50% compared to initial result (at least a day before) 5. increase of il-6 by at least 25% compared to initial result (at least a day before) 6. progression of lung changes in ct compared to initial picture (assessed in covid-ct scale; at least a day before) 7. decline of pao2/fio2 by at least 100 mmhg, but not lower than 200 mmhg